BLUETTI to Release AC180, Making Another Breakthrough in Portable Power Station Area
21.4.2023 13:16:00 EEST | Business Wire | Press release
Spring camping has gradually become popular in recent years, providing a precious chance for people to get rid of the hustle and bustle of urban life and have close contact with nature. However, most of their trips experienced mobile power shortages out there.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230421005196/en/
(Photo: Business Wire)
BLUETTI, a market leader in the energy storage industry, is about to unveil a brand-new model. As a successor of the previous portable stations such as EB150 and EB240, AC180 is designed with a bunch of improvements that kit it up a notch, making it a well-deserved portable power station for emergency backup, sudden blackouts, excursions, and more.
Explore Outdoors with Great Capacity
To help elevate the off-grid lifestyle, BLUETTI equips AC180 with a 1800W constant output power and 1.152Wh capacity, covering almost all power demands of essentials at home or in the wild. Furthermore, AC 180 also comes with a Power Lifting Mode of 2.700W output to effortlessly run high-powered devices like kettles, hair dryers, microwaves, etc.
Besides, AC180 is updated with a 1,7-inch LCD display and bigger font size to make the power consumption and troubleshooting status more visualized and clearly.
Travel with Grab-and-go Power
Pack lighter, travel further. In view of portability, AC180 is ultra compact for effortless transportation as it measures 340mmｘ247mmｘ317mm (H x W x H) and weighs only 35kg. It does not occupy too much space of the truck on the way to the next campsite.
Recharge with High Speed
For outdoor enthusiasts looking for backup power for their camping or RV trips on the road, AC180 is sure to exceed their expectations. Even exploring off the beaten track far from the main grid, the reliable power source is always on call as AC180 supports up to 1.440W Turbo Charging, 0-80% SOC only takes about 45mins! Get it charged before packing up for the getaway, a large amount of power is ready to hit the road when you are.
Live with Uninterrupted Power Supply
Given the UPS system, there’s no need to worry about losing data or hardware damage in the event of a power outage since AC180 can automatically detect the blackout the moment it occurs and seamlessly switch over in 20ms that no one can even be aware of.
Constant Power with Peace of Mind
Keeping high security and longevity in mind, BLUETTI adopts safe and durable LiFePO4 battery cells and guarantees a worry-free warranty for as long as 5 years, which really sets it apart from most competitors throughout the market.
Remotely monitoring AC180 in real time is a no-brainer thanks to the intelligent BLUETTI APP. Now setting up working modes, checking the system conditions, and OTA updates can be done solely with fingertips.
“We’re dedicated to more innovations that’s a right fit for the increasing market demand. Our R&D team once envisioned a power station integrated with portability, capability, and cost performance, and now we’ve made it come true. AC180 has everything users could possibly need without costing an arm and a leg,” said James Ray, the marketing director of BLUETTI.
Availability
Though the debut price is not finally decided yet, it’s believed to be the most affordable power station that worth the wait.
About BLUETTI
From the very beginning, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for our homes and our world. That's why BLUETTI makes its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online at https://www.bluettipower.eu/ or follow BLUETTI on:
YouTube: https://www.youtube.com/c/bluettiofficial
Facebook: https://www.facebook.com/bluettipower.eu/
Twitter: https://twitter.com/bluetti_inc
Instagram: https://www.instagram.com/bluetti_europe/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005196/en/
Contact information
jacinda@bluetti.com
130 4085 7737
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom